Last €4.16 EUR
Change Today +0.072 / 1.76%
Volume 550.0
V3V On Other Exchanges
As of 3:02 AM 10/2/14 All times are local (Market data is delayed by at least 15 minutes).

vita 34 ag (V3V) Snapshot

Previous Close
Day High
Day Low
52 Week High
01/13/14 - €8.50
52 Week Low
10/8/13 - €2.64
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for VITA 34 AG (V3V)

Related News

No related news articles were found.

vita 34 ag (V3V) Related Businessweek News

No Related Businessweek News Found

vita 34 ag (V3V) Details

VITA 34 AG, through its subsidiaries, operates as an umbilical cord blood bank in Germany, Austria, Switzerland, and Spain. The company operates through Stem Cell Storage and Biotechnology segments. The Stem Cell Storage segment collects, processes, and stores stem cells from umbilical cord blood and umbilical cord tissue, as well as develops cell therapy procedures. The Biotechnology segment develops biological processes for cell and tissue culture, as well as employs them in the optimization and multiplication of cells and plants. It offers VitaPlusDonation that offers parents an alternative to the purely autologous storage or allogenic donation of umbilical cord blood; and Sibling Initiative program, which allows the storage free of charge of stem cells from the umbilical cord of a child whose brother or sister is seriously ill. The company also provides Prevention Screening that helps to detect genetically related health risks and predispositions; and mobile stem cell team to ensure the treatment with stem cells from umbilical cord blood in hospital. VITA 34 AG was founded in 1997 and is headquartered in Leipzig, Germany.

106 Employees
Last Reported Date: 07/24/14
Founded in 1997

vita 34 ag (V3V) Top Compensated Officers

Chief Executive Officer and Member of Managem...
Total Annual Compensation: €264.0K
Chief Financial Officer, Managing Director an...
Total Annual Compensation: €204.0K
Compensation as of Fiscal Year 2013.

vita 34 ag (V3V) Key Developments

VITA 34 AG Presents at DVFA 12th Small Cap Conference, Sep-01-2014 02:50 PM

VITA 34 AG Presents at DVFA 12th Small Cap Conference, Sep-01-2014 02:50 PM. Venue: DVFA Center, Mainzer Landstr. 37-039, 60329 Frankfurt am Main, Germany. Speakers: André Gerth, Chief Executive Officer and Member of Management Board.

Vita 34 AG Announces Executive Changes

The supervisory board of Vita 34 AG elected Dr. Hans-Georg Giering, so far vice chairman of the supervisory board, as the new chairman. He takes over the position from Dr. Holger F-disch with immediate effect. Dr. F-disch will continue to actively support the corporation as vice chairman of the supervisory board in the future.

VITA 34 AG Reports Earnings Results for the First Half of 2014

VITA 34 AG reported earnings results for the first half of 2014. For the period, the company earned operating income in the amount of EUR 6.6 million against EUR 6.9 million a year ago. In comparison with the prior year revenues decreased by 6.3% from EUR 6.5 million to EUR 6.1 million. Earnings before interest, taxes, depreciation and amortization were EUR 0.8 million against EUR 0.9 million a year ago. EBIT was also stable as compared with the prior year at EUR 0.3 million, and the group result was increased by 67% to EUR 114,000 against EUR 68,000 a year ago.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
V3V:GR €4.16 EUR +0.072

V3V Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for V3V.
View Industry Companies

Industry Analysis


Industry Average

Valuation V3V Industry Range
Price/Earnings 12.8x
Price/Sales 0.9x
Price/Book 0.5x
Price/Cash Flow 12.8x
TEV/Sales 0.5x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact VITA 34 AG, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at